Featured Trials

Not all clinical trials are the same. That’s why our review team of patients and researchers helped to identify trials we believe are going above and beyond for patients and families; our Featured Trials. For your safety and to protect your rights, these and all other clinical trials are reviewed by an Institutional Review Board (IRB).

Researchers

Just like you, we believe in a better tomorrow where everyone finds the cure they desperately seek. Is there a clinical trial you'd like to see featured on the CTSS website?

Apply Here

Patients & Caregivers

Every day, we strive to lead with clarity to keep overwhelm at bay. Do you have questions that need answers? Would you like to participate in a featured trial?

A drug, linvoseltamab, compared to standard of care, to treat multiple myeloma that has come back (relapsed) or has not gotten better with treatment (refractory)
To find out if linvoseltamab is safe and works well to treat multiple myeloma that has relapsed or is refractory
A drug, RLS-0071 , alone or with ruxolitinib, to treat acute graft-versus-host disease (GVHD) that has not gotten better with treatment (refractory) in children and adults
To find out:
- The highest dose of RLS-0071 that’s safe to give with ruxolitinib
- If the combination of RLS-0071, alone or with ruxolitinib, is safe and works well to treat acute GVHD that is refractory to steroids
Allogeneic (cells from a donor) blood or marrow transplant (BMT) using cells from a deceased donor to treat acute leukemia
To find out if allogeneic BMT using cells from a deceased donor is safe and works well to treat acute leukemia
A mobile phone application (app) to improve sleep disturbance in adults diagnosed with a blood cancer
To find out if an app-based wellness program helps to reduce sleep disturbances in adults with a blood cancer diagnosis
Cytokine-induced memory-like (CIML) natural killer (NK) cells from a haploidentical (half-matched) donor, to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory)
To find out if CIML-NK cells are safe and work well to treat AML that has relapsed or is refractory
Engineered donor graft (donor cells treated in a lab) for children and adults getting allogeneic (cells from a donor) blood or marrow transplant (BMT) to treat blood cancer
To find out if an engineered donor graft is safe and works well to treat blood cancer in children and adults getting an allogeneic BMT
Gene therapy, using T cells (HA-1 TCR) from a donor, to treat acute leukemia that has come back (relapsed) after getting an allogeneic (cells from a donor) blood or marrow transplant (BMT)
To find out:
- The highest dose of HA-1 TCR T cells that is safe to give
- If HA-1 TCR T cells are safe and work well to treat acute leukemia that has relapsed after allogeneic BMT
Two drugs, isatuximab and lenalidomide, to treat multiple myeloma that doctors consider high-risk after autologous (your own cells) blood or marrow transplant (BMT)
To find out if the combination of isatuximab and lenalidomide is safe and works well to treat multiple myeloma that doctors consider high-risk after autologous BMT
No Longer Recruiting
A drug, apraglutide, to treat acute graft-versus-host disease (GVHD) that has not gotten better with treatment (refractory)
To find out if apraglutide is safe and works well to treat GVHD that is refractory
No Longer Recruiting
A drug, belumosudil, to treat chronic graft-versus-host disease (GVHD) in children and adults who are ethnically diverse
To find out if belumosudil is safe and works well to treat chronic GVHD in children and adults who are ethnically diverse
No Longer Recruiting
A drug, belumosudil, to treat chronic graft-versus-host disease (GVHD) in children, teens and young adults
To find out if belumosudil is safe and works well to treat chronic GVHD in children, teens and young adults
No Longer Recruiting
A drug, itolizumab, in combination with steroids, to treat acute graft-versus-host disease (GVHD)
To find out if itolizumab, in combination with steroids, is safe and works well to treat acute GVHD
No Longer Recruiting
A drug, MT-401 (zedenoleucel), to treat acute myeloid leukemia (AML)
To find out if zedenoleucel is safe and works well to treat AML
No Longer Recruiting
A drug, REGN7257, to treat severe aplastic anemia (SAA) that has come back (relapsed) or has not gotten better with treatment (refractory)
To find out:
- The highest dose of REGN7257 that’s safe to give
- If REGN7257 is safe and works well to treat SAA that has relapsed or is refractory
No Longer Recruiting
A drug, SER-155, to reduce the risk of infection and graft-versus-host disease (GVHD) after allogeneic (cells from a donor) blood or marrow transplant (BMT)
To find out if SER-155 is safe and works well to reduce infection and GVHD after allogeneic BMT
No Longer Recruiting
Allogeneic (cells from a donor) blood or marrow transplant (BMT) or immunosuppressive therapy to treat severe aplastic anemia (SAA) that has not yet been treated in children, teens and young adults (TransIT, BMT CTN 2202)
To find out whether allogeneic BMT or immunosuppressive therapy is more effective in treatment of SAA that has not yet been treated in children, teens and young adults
No Longer Recruiting
Allogeneic (cells from a donor) blood or marrow transplant (BMT) with an unrelated mismatched donor and post-transplant cyclophosphamide (PTCy) to treat blood cancers in children and adults
To find out if allogeneic BMT with an unrelated mismatched donor and PTCy is safe and works well to treat blood cancers in children and adults
No Longer Recruiting
CAR T cells (CD33CART) to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory) in children and young adults
To find out:
- The highest dose of CD33CART that is safe to give
- If CD33CART is safe and works well to treat AML that has relapsed or is refractory in children and young adults
No Longer Recruiting
Donor Search Prognosis (DSP) score to help choose the best donor before allogeneic (cells from a donor) blood or marrow transplant (BMT)
To find out if donor selection based on an individual’s DSP score gets patients to allogeneic BMT more quickly and with better outcomes.
No Longer Recruiting
Two drugs, eculizumab or ravulizumab,in combination with cemdisiran and pozelimab, to treat paroxysmal nocturnal hemoglobinuria (PNH)
To find out if eculizumab or ravulizumab, in combination with cemdisiran and pozelimab, is safe and works well to treat PNH.
No Longer Recruiting
Viral specific T cells (VSTs), posoleucel (ALVR105), to prevent viral infections after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults
To find out if posoleucel is safe and works well to prevent viral infections after allogeneic BMT in children and adults
No Longer Recruiting
Viral specific T cells (VSTs), posoleucel, to treat adenovirus infection after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults
To find out if posoleucel is safe and works well to treat adenovirus infection after allogeneic BMT in children and adults
No Longer Recruiting
Viral specific T cells (VSTs), posoleucel, to treat virus-associated hemorrhagic cystitis (HC) after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults
To find out if posoleucel is safe and works well to treat virus-associated HC after allogeneic BMT in children and adults

Welcome to the Jason Carter Clinical Trials Website

Featured Trials

Researchers

Patients & Caregivers

A drug, apraglutide, to treat acute graft-versus-host disease (GVHD) that has not gotten better with treatment (refractory)

A drug, belumosudil, to treat chronic graft-versus-host disease (GVHD) in children and adults who are ethnically diverse

A drug, belumosudil, to treat chronic graft-versus-host disease (GVHD) in children, teens and young adults

A drug, itolizumab, in combination with steroids, to treat acute graft-versus-host disease (GVHD)

A drug, MT-401 (zedenoleucel), to treat acute myeloid leukemia (AML)

A drug, REGN7257, to treat severe aplastic anemia (SAA) that has come back (relapsed) or has not gotten better with treatment (refractory)

A drug, SER-155, to reduce the risk of infection and graft-versus-host disease (GVHD) after allogeneic (cells from a donor) blood or marrow transplant (BMT)

Allogeneic (cells from a donor) blood or marrow transplant (BMT) or immunosuppressive therapy to treat severe aplastic anemia (SAA) that has not yet been treated in children, teens and young adults (TransIT, BMT CTN 2202)

Allogeneic (cells from a donor) blood or marrow transplant (BMT) with an unrelated mismatched donor and post-transplant cyclophosphamide (PTCy) to treat blood cancers in children and adults

CAR T cells (CD33CART) to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory) in children and young adults

Donor Search Prognosis (DSP) score to help choose the best donor before allogeneic (cells from a donor) blood or marrow transplant (BMT)

Two drugs, eculizumab or ravulizumab,in combination with cemdisiran and pozelimab, to treat paroxysmal nocturnal hemoglobinuria (PNH)

Viral specific T cells (VSTs), posoleucel (ALVR105), to prevent viral infections after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults

Viral specific T cells (VSTs), posoleucel, to treat adenovirus infection after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults

Viral specific T cells (VSTs), posoleucel, to treat virus-associated hemorrhagic cystitis (HC) after an allogeneic (cells from a donor) blood or marrow transplant (BMT) in children and adults